Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.

Completed · Phase 1

Conditions studied: Parkinson Disease

In brief

This study aims to determine if one of three low doses of lithium therapy for 6 months can engage one or more blood-based therapeutic targets implicated in Parkinson's disease (PD) pathophysiology. Results of this study will help to determine if lithium therapy is worthwhile to further investigate as a potential disease-modifying therapy in PD, the optimal dose to study and the optimal PD subgroup most likely to benefit from lithium therapy.

Key facts

Study ID
NCT04273932
Run by
State University of New York at Buffalo
People needed
19
Starts
2019-10-17
Expected to finish
2023-08-12
Last updated by the study team
2023-08-15

Who can join

Age: 45 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.